This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2003;26(8 Suppl):39-45.

The treatment algorithm of acromegaly

A Colao¹, R Pivonello, P Cappabianca, G Vitale, G Lombardi

Affiliations

PMID: 15233211

Review

The treatment algorithm of acromegaly

A Colao et al. J Endocrinol Invest. 2003.

. 2003;26(8 Suppl):39-45.

Authors

A Colao¹, R Pivonello, P Cappabianca, G Vitale, G Lombardi

Affiliation

¹ Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University, Naples, Italy. colao@unina.it

PMID: 15233211

No abstract available

PubMed Disclaimer

Similar articles

Multimodality treatment of pituitary adenomas.
Oyesiku NM. Oyesiku NM. Clin Neurosurg. 2005;52:234-42. Clin Neurosurg. 2005. PMID: 16626076 No abstract available.
The effects of somatostatin analogs on tumor shrinkage in acromegaly.
Pedroncelli AM, Montini M, Albizzi M, Barbò R, Pagani G. Pedroncelli AM, et al. J Endocrinol Invest. 2003;26(8 Suppl):50-4. J Endocrinol Invest. 2003. PMID: 15233213 Review. No abstract available.
The effects of somatostatin analogs on biochemical parameters in acromegaly.
Liuzzi A, Marzullo P. Liuzzi A, et al. J Endocrinol Invest. 2003;26(8 Suppl):46-9. J Endocrinol Invest. 2003. PMID: 15233212 Review. No abstract available.
Rationale of pre-surgical medical treatment with somatostatin analogs in acromegaly.
Cappabianca P, Cavallo LM, Esposito F, Romano I, Colao A, de Divitiis E. Cappabianca P, et al. J Endocrinol Invest. 2003;26(8 Suppl):55-8. J Endocrinol Invest. 2003. PMID: 15233214 Review. No abstract available.
Conclusions: the future role of somatostatin analogs.
Lamberts SW. Lamberts SW. J Endocrinol Invest. 2003;26(8 Suppl):134-5. J Endocrinol Invest. 2003. PMID: 15233230 No abstract available.

See all similar articles

Cited by

Potential role of type I interferons in the treatment of pituitary adenomas.
Vitale G, Caraglia M, van Koetsveld PM, Maroni P, Marra M, Colao A, Lamberts SW, Cavagnini F, Hofland LJ. Vitale G, et al. Rev Endocr Metab Disord. 2009 Jun;10(2):125-33. doi: 10.1007/s11154-008-9083-3. Epub 2008 Jul 6. Rev Endocr Metab Disord. 2009. PMID: 18604644 Review.
Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study.
Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R, Angeletti G. Grottoli S, et al. J Endocrinol Invest. 2005 Dec;28(11):978-83. doi: 10.1007/BF03345335. J Endocrinol Invest. 2005. PMID: 16483175

Publication types

Actions

MeSH terms

Substances

LinkOut - more resources

Medical
- MedlinePlus Health Information